Get started
Author

Sung Chul Hong

Observed institution: Dana-Farber Cancer Institute
OpenAlex ID: A5060878232
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
2022 · Jennifer Rachel Eads, Paul J. Catalano, et al. · Journal of Clinical Oncology · 14
Optimal perioperative therapy for incidental gallbladder cancer (OPT-IN): A randomized phase II/III trial—ECOG-ACRIN EA2197.
2023 · Shishir K. Maithel, Sung Chul Hong, et al. · Journal of Clinical Oncology · 11
APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation—ECOG-ACRIN EA2192.
2023 · Kim Anna Reiss, Sung Chul Hong, et al. · Journal of Clinical Oncology · 10
EA2201: An ECOG-ACRIN phase II study of neoadjuvant nivolumab plus ipilimumab and short course radiation in MSI-H/dMMR rectal tumors.
2022 · Kristen Keon Ciombor, Sung Chul Hong, et al. · Journal of Clinical Oncology · 8
Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.
2023 · Kim Anna Reiss, Sung Chul Hong, et al. · Journal of Clinical Oncology · 4
PDF
Works count: 5
Citation count: 47
H-index: 4
I10-index: 3
Year
Topic
Type